Hydroxychloroquine / azithromycin in COVID-19: The association between time to treatment and case fatality rate
Autor: | Lidia M. López, Grisel Jesús Ynga-Meléndez, Juan Diego Mendoza-Saldaña, Juan Alonso Leon-Abarca, Juan Carlos Madrid-Cisneros, Roberto A. Accinelli |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
vomiting
myalgia Multivariate analysis time to treatment very elderly diarrhea rash Azithromycin Logistic regression Hydroxychloroquine (HCQ) Coronavirus disease 2019 (COVID-19) newborn Peruvian Peru Case fatality rate Medicine pain ageusia Maternal-Infant Center (MIC) outpatient care fever child case fatality rate adult primary medical care chill nausea backache sore throat Mean Cytotoxic Concentration (CC50%) aged comorbidity female Infectious Diseases Mean Maximum Inhibitory Concentration (MIC50%) drug withdrawal Drug Therapy Combination Female headache medicine.drug Hydroxychloroquine Adult medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Time to treatment nose obstruction Article Time-to-Treatment coronavirus disease 2019 male Internal medicine Humans irritability Selectivity Index (SI) human arthralgia decreased appetite Mortality coughing dizziness unspecified side effect business.industry SARS-CoV-2 abdominal pain thorax pain Public Health Environmental and Occupational Health COVID-19 dyspnea medicine.disease infant major clinical study Comorbidity clinical feature COVID-19 Drug Treatment eye redness Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Oxygen Saturation disease duration business Angiotensin converting enzyme 2 (ACE2) body temperature anosmia Azithromycin (AZIT) Mean Effective Concentration (EC50) |
Zdroj: | Travel Medicine and Infectious Disease |
ISSN: | 1873-0442 1477-8939 |
Popis: | Background Currently, there is no formally accepted pharmacological treatment for COVID-19. Materials and methods We included COVID-19 outpatients of a Peruvian primary care center from Lima, Peru, who were treated between April 30 - September 30, 2020, with hydroxychloroquine and azithromycin. Logistic regression was applied to determine factors associated with case-fatality rate. Results A total of 1265 COVID-19 patients with an average age of 44.5 years were studied. Women represented 50.1% of patients, with an overall 5.9 symptom days, SpO2 97%, temperature of 37.3 °C, 41% with at least one comorbidity and 96.1% one symptom or sign. No patient treated within the first 72 h of illness died. The factors associated with higher case fatality rate were age (OR = 1.06; 95% CI 1.01–1.11, p = 0.021), SpO2 (OR = 0.87; 95% CI 0.79–0.96, p = 0.005) and treatment onset (OR = 1.16; 95% CI 1.06–1.27, p = 0.002), being the latter the only associated in the multivariate analysis (OR = 1.18; 95% CI 1.05–1.32, p = 0.005). 0.6% of our patients died. Conclusions The case fatality rate in COVID-19 outpatients treated with hydroxychloroquine/azithromycin was associated with the number of days of illness on which treatment was started. |
Databáze: | OpenAIRE |
Externí odkaz: |